Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference 2023-11-14 20:47
HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO 2023-11-14 08:27
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023 2023-11-14 06:40
OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002 2023-11-13 22:00
PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE 2023-11-13 21:00
Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates 2023-11-13 16:04
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results 2023-11-10 08:00
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data 2023-11-09 21:00
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases 2023-11-09 15:05
Porton Advanced Announces a Strategic Partnership with BioMap, with AI Models Facilitating AAV Gene Therapy Development 2023-11-08 22:31
WuXi Biologics Receives AAA MSCI ESG Rating 2023-11-08 08:30
Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial 2023-11-07 21:58
Kexing Biopharm Attended CPHI Worldwide 2023 2023-11-07 20:09
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) 2023-11-07 20:00
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate 2023-11-07 14:14
87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting 2023-11-07 12:31
Lerna Bio unveils its first-in-class solution to combat liver failure 2023-11-06 22:00
I-Mab Announces Participation at Jefferies and Piper Conferences in November 2023-11-06 21:00
The World's First "Recombinant Anthrax Vaccine": GC Biopharma applies for MFDS Approval 2023-11-06 09:11
Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy 2023-11-05 08:00
1 32 33 34 35 36 165